The Global Health Body Issues Warning Over Acute Scarcity of Obesity Injections
Less than one in 10 individuals that would benefit from obesity jabs including Wegovy can access them, caution the global health agency as it publishes its inaugural recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide now classified as obese, it is urging more widespread and fairer availability to GLP-1 medication.
According to projections, more than two billion could be living with obesity by 2030 unless action is taken.
"Our new guidance acknowledges that excess weight is a lifelong illness that can be addressed with thorough and ongoing care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are significant hurdles to broad availability to the injections that can assist patients in reducing substantial weight, notes the agency.
Weight-Loss Drug Shortage
Even under the current best projected case, the production of these medications could only cover approximately 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The advice encourages countries and companies to expand access, through measures like voluntary licensing.
Exclusive production rights on semaglutide – the primary component of a leading brand – is due to expire in a number of countries in 2026.
How Weight-Loss Injections Operate
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, reduce hunger and increase feelings of fullness so individuals reduce food intake.
Individuals typically see weight reduction after several weeks of commencing the weekly injections.
Evidence points to users may regain a significant portion within a year of halting the drug, as their typical food cravings come back.
To be carrying excess weight raises your likelihood for experiencing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight affects individuals in all nations and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.
